Peter Halliburton (@phalliburton) header
Peter Halliburton (@phalliburton) profile picture

Raising $ for SYNGAP1 🧬 gene therapy // ex-BoD @cureSYNGAP1 501(c)(3) // Carter & P’s Dad // @paloaltonetworks Channel // Building a small compound in TX 🇨🇱

McKinney, TX
Joined January 2010
Photo by Peter Halliburton (@phalliburton)Photo by Peter Halliburton (@phalliburton)Photo by Peter Halliburton (@phalliburton)Photo by Peter Halliburton (@phalliburton)Photo by Peter Halliburton (@phalliburton)Photo by Peter Halliburton (@phalliburton)Photo by Peter Halliburton (@phalliburton)Photo by Peter Halliburton (@phalliburton)Photo by Peter Halliburton (@phalliburton)Photo by Peter Halliburton (@phalliburton)
For Carter’s 3rd birthday this past May, we created a video on our journey to getting a #Syngap1 dx via @Invitae, and the hope we’ve found in @SyngapRF & @SyngapNetwork to find therapies for our children in a timeframe that matters. This is our story. #ID #Epilepsy #LGS #Autism – at McKinney, TX
2
17
2
77
Peter Halliburton retweeted
This #NationalFamilyCaregiversMonth, we recognize the families supporting loved ones living with #SYNGAP1 and the daily challenges they navigate, including sleep disturbances and seizures.​ Learn more about resources for families: bit.ly/4zwJLPJ
1
2
76
Peter Halliburton retweeted
The U.S. government has approved the Secure SI by Design Consortium. We're leading the coalition alongside @nvidia, @IBM, @OpenAI, @Snowflake, @Cognizant, @reflection_ai, @factory, and @ServiceNow to help bring full-stack SI with built-in cybersecurity to allies and partners. See what this means for secure SI adoption worldwide. bit.ly/48ZUne5
23
19
7
109
17,486
Peter Halliburton retweeted
So what the industry tried to warn enterprises about 6 months ago is here. The events of this week so far are not a coincidence. AI is making it easy for hackers to attack multiple customers. All incident responders are busy, unfortunately there is no silver bullet. If you haven't: - run a multi model testing harness across your infrastructure. - patch your code - find virtual patching solutions for open source When it happens, because it will. Your SOC should be ready to detect and remediate in record time. REVAMP your SOC to a real time data lake with proactive ML detectors across your data, with AI running correlation if you want a chance to come out ahead. Band-aid reactive solutions which work on multiple data lakes is not a plan.
116
402
97
3,276
645,630
Peter Halliburton retweeted
We’re excited to announce that we’ve received clearance from the European Medicines Agency to begin our Phase 1/2 clinical trial of CMP-002 in #SYNGAP1 patients in the European Union. Read more in our press release: bit.ly/4ii9ZiN
1
6
301
Peter Halliburton retweeted
We discovered a sophisticated recording device that was hidden inside one of our offices. We used our models to understand the device and where it had come from, identifying that a specific employee had planted it a few days earlier. We referred the matter to the FBI, and we’re grateful to the agents and prosecutors who moved quickly to make an arrest. The FBI’s investigation is ongoing and we will continue to support their work. At this time, we have no indications of this individual inappropriately accessing or exfiltrating model weights, source code, or customer data. The employee was terminated. We take protecting our technology, data, and people seriously, and as a matter of national importance. Our security program is designed to protect against a wide range of threat actors, from insider risks to cybercriminals to nation states, and this case is an example of how AI can help address these sophisticated security threats.
4,110
6,037
5,728
77,161
26,247,549
Peter Halliburton retweeted
Claude has discovered a previously unknown enzyme system hidden in the DNA of bacteriophages. Beside the enzyme’s gene sits a long array of repeating DNA—a structure that looks somewhat similar to CRISPR. We don’t yet understand what this system does, but only a handful of known systems share its features, and all of them are able to cut, copy, and paste DNA. Historically, the discovery of such programmable systems has helped revolutionize medicine. CRISPR, for instance, is now the foundation of genetic medicines. But it will take much more work to learn what this system does, and whether it can be put to similar use. Read more: anthropic.com/news/claude-di…
1,542
5,273
2,638
40,708
25,782,588
Peter Halliburton retweeted
We’re partnering with @Anthropic to launch the biggest Protein Design Competition in the world, challenging people around the world to use AI to design new potential drug candidates for diseases that affect millions of lives. The competition will feature five challenges, each focused on a specific disease or biological mechanism. Compared to previous competitions, it will be a big step-up in complexity and scale to push the boundaries of AI-driven protein design. Together with Anthropic, we’re sponsoring over $1 million in experimental validation, making it possible to test more than 5,000 protein designs in our automated lab at no cost to participants. Anthropic is providing an additional $1 million in Claude credits. All experimental results will be published openly on @Proteinbase, including designs that didn’t work, so anyone can access the data and build on what we learn. The competition is open to everyone and free to enter. It will feature 3 tracks: - Track 1 is aimed at expert protein designers, with up to 20 teams to be selected. - Track 2 is targeting life science academics and industry researchers. - Track 3 is open to everyone from tech enthusiasts to high-school students. By combining Anthropic’s models with access to our automated lab, we want to make it possible for anyone with a laptop and an internet connection to join the global effort to advance human health with AI. A big thanks to @Modal for contributing compute for protein design and to @TwistBioscience for contributing the DNA for the experimental validation! Sign up link below -
33
146
43
832
210,285
Peter Halliburton retweeted
Big Short investor Steve Eisman says the AI labs know they have no moats and are manufacturing a crisis to get regulation that hands them a duopoly "I think this is all nonsense." [ You think it's all nonsense? ] "All nonsense. I think that there's something else completely going on here. ... What I think is happening is that token maxing is over. The open weight models are taking big market share. I think these companies are very nervous. They realize that there are no moats around their business whatsoever, and they're trying to manufacture a crisis that will create regulation, and that they think they can then manipulate to create the moats, to create the duopoly that they want." [ Wow. ] "That's what I think is going on." "Honestly, I think this whole Terminator thing is garbage. That's for sure."
342
2,511
380
13,291
3,134,751
Peter Halliburton retweeted
Today we’re opening applications for the Life Sciences Verification Program. Through the LSVP, life science professionals can use our models—including, for the first time, Mythos—with a new set of safeguards designed to enable the full range of biology-related work. We designed these new safeguards to provide a better experience for biologists and more protection from risk of misuse. The program is launching in beta for teams of all kinds—from academic labs to startups, pharma companies, and more. We will continue to improve the program and expand access to individual Pro and Max plans over time. Learn more about these access grants and apply: anthropic.com/news/life-scie…
226
316
127
2,709
586,398
Peter Halliburton retweeted
Security and IP implications of AI The case for rapid AI deployment - I think we can all conclude the following from the last few months of developments - 1. Not using AI could and will become an existential issue for both individual users and enterprises. 2, Enterprise adoption will be cautious while individual users are definitely going to race ahead, try different use cases, build agents, push the models to their limits (although it seems harder to do, unless you live in an AI Lab) 3. Employees and developers will take matters in their own hands since they will find their cautious enterprises aren't moving fast enough. 4. Agents are showing their prowess, uncontrolled, unrestrained agents with a "capture the flag mentality" are showing us the edge cases which demonstrate the negative outcome possiblities of these scenarios. 5. It is impossible to plan for the next 6 months since we can't fathom where technology will evolve to. These activities will cause adoption sans security..... AI has deep implications on security in the future. In this environment security companies need to live on the bleeding edge, anticipating scenarios, building framework solutions so we have a shot at securing future outcomes. Which we all are. Some useful pointers to people planning their AI implementation: 1. Secure what you plan to use, try not to secure the future - no products for security can be created unless we see the future unfold. The future is moving fast, so are we. 2. Most of the coding usage is unsecured. Make sure your coding is secure. Most enterprise AI apps do not offer a secure instance (this is your IP living in their instance)! SECURE your codex, cursor, Claude code Harvey, glean, legora instances now! 3. Do not try and build your own - I have already experienced enterprise customers building gateways and tools for agents - security companies have thousands of specialists working on this, leverage them, Focus on AI adoption instead. Partner to secure. 4. Securing agents is a complex problem - securing the agentic lifecycle - real time inspection and kill switches are key. Don't fall in the discovery and posture trap (Visibility - process understanding - intent interpretation - ability to stop inline are key tenets to the agentic lifecycle - not identity, posture and inventory - those are mere building blocks) 5. Only use enterprise protected models, single tenant, firewalled, inspected implementations - this is your IP you are playing with - LLMs have shown they will cross boundaries to capture the flag - you think your IP is safe? Once you train an unprotected model with your IP - you can't reverse the trade. 6. Perhaps the most important one - do not use a security tool built by the same person who is selling you the AI implementation, historically IT vendors are different from security vendors. You need an enterprise solution for security and it must work on your diverse infrastructure. Use a pure play security partner. Happy building with AI.
83
119
32
1,149
1,660,822
Peter Halliburton retweeted
Anthropic CEO Dario Amodei stated that artificial intelligence could make it possible to cure most human diseases within 5 to 10 years.
314
158
136
2,491
390,736
Peter Halliburton retweeted
In this #CAMP4Fireside Series, our CSO, Dan Tardiff, PhD, discusses why #SYNGAP1 & #HaploinsufficientDiseases are ideal targets for gene upregulation & how our approach aims to increase #GeneExpression through our #regRNA-targeting platform. Learn more: bit.ly/4ekBntf
1
1
109
My 9y/o has SYNGAP1-RD: epilepsy, ID, nonverbal autism, & severe behaviors. He’s had a remarkable seizure response to repurposed 4-PBA, though mechanism is unclear. Paradoxical effect to most behavior Rx & desperate. Will open-source full med/genomic data via Citizen Health.
There is a child with a rare disease who is currently suffering and struggling to manage his symptoms. Rare as this is, you can directly help him. Today we are launching the "Rare Disease, Real Kid" Hackathon, and there are $50,000 in prizes from @AnthropicAI and @awscloud. We (@huggingface & @Sagebio) are helping this child open his genome and clinical data to the community, so that we can find what's caused his disease and what currently-approved drugs could help him. I doubt I need to motivate this much further or explain how rare it is for a family to share their child's genome and clinical data, but if you're not sure, consider this: Until very recently, it wasn't feasible for patients like this to get treatment because their disease was so rare that the economics could never justify the investment. Now, as we've seen, people with rare diseases are starting to be able to find the answers themselves (with the help of AI tools, cheaper sequencing, etc). This kid is not able to do that for himself and neither are his parents, so we're asking you for help. Both for this kid and to prove that it's possible for everyone else suffering from a rare disease. More details in 🧵. sagebio-rare-disease-real-ki…
3
171
Peter Halliburton retweeted
frontier labs making moves in rare at first it’s $50k then it’ll be $500k then $5M then $50M then we start cooking with gas
There is a child with a rare disease who is currently suffering and struggling to manage his symptoms. Rare as this is, you can directly help him. Today we are launching the "Rare Disease, Real Kid" Hackathon, and there are $50,000 in prizes from @AnthropicAI and @awscloud. We (@huggingface & @Sagebio) are helping this child open his genome and clinical data to the community, so that we can find what's caused his disease and what currently-approved drugs could help him. I doubt I need to motivate this much further or explain how rare it is for a family to share their child's genome and clinical data, but if you're not sure, consider this: Until very recently, it wasn't feasible for patients like this to get treatment because their disease was so rare that the economics could never justify the investment. Now, as we've seen, people with rare diseases are starting to be able to find the answers themselves (with the help of AI tools, cheaper sequencing, etc). This kid is not able to do that for himself and neither are his parents, so we're asking you for help. Both for this kid and to prove that it's possible for everyone else suffering from a rare disease. More details in 🧵. sagebio-rare-disease-real-ki…
5
3
46
10,548
Peter Halliburton retweeted
There is a child with a rare disease who is currently suffering and struggling to manage his symptoms. Rare as this is, you can directly help him. Today we are launching the "Rare Disease, Real Kid" Hackathon, and there are $50,000 in prizes from @AnthropicAI and @awscloud. We (@huggingface & @Sagebio) are helping this child open his genome and clinical data to the community, so that we can find what's caused his disease and what currently-approved drugs could help him. I doubt I need to motivate this much further or explain how rare it is for a family to share their child's genome and clinical data, but if you're not sure, consider this: Until very recently, it wasn't feasible for patients like this to get treatment because their disease was so rare that the economics could never justify the investment. Now, as we've seen, people with rare diseases are starting to be able to find the answers themselves (with the help of AI tools, cheaper sequencing, etc). This kid is not able to do that for himself and neither are his parents, so we're asking you for help. Both for this kid and to prove that it's possible for everyone else suffering from a rare disease. More details in 🧵. sagebio-rare-disease-real-ki…
123
491
190
3,169
669,751
Extremely exciting news for the @cureSYNGAP1 community. We’re eagerly watching from the US and hopeful to see this momentum extend to American patients soon! Our families are ready [read: desperate] to bring a disease-modifying therapy to our children!
ICYMI: Our CEO Josh Mandel-Brehm joined @CNBC Cures' @BeckyQuick to discuss our first-in-human trial for #SYNGAP1-related disorder, including new regulatory approvals in Australia & Argentina and our approach to restoring SYNGAP protein expression. ​Watch: cnb.cx/4wEgdxW
2
280
Peter Halliburton retweeted
If you want clinical trial abundance and the fastest in-human validation loop, may I present 1000s of rare monogenic disease communities, some as small as two or three families, all eager and willing to participate in trials, starting with N-of-1.
2
8
82
5,765
Peter Halliburton retweeted
Anthropic benchmarked their newest Claude models on protein engineering tasks, and we at @adaptyvbio ran the wet lab work behind it. They picked 16 targets from our past protein design competitions on @proteinbase and sent us an anonymised list of designs, so we had no idea which model produced which sequence. We then ran those protein designs through our automated wet lab workflow to characterize protein expression and binding affinities. Here are the results: - 95% of the designs expressed, which three years ago would have been the headline on its own. That matches the best expert expression rates from our competitions - 354 of 1,320 designs bound their target on SPR, a 26.8% hit rate overall. Claude got binders on 14 of the 15 targets we could evaluate. Compared to our own data from public competitions, Claude beat de novo hit rates, for one target by more than three times the rate on Proteinbase So can AI now solve all diseases? Well no, not yet. This case study shows that Claude is at least expert-level at orchestrating protein design tools. That’s great news, since protein design tools are hard to use. Before AI, even setting up a protein structure prediction tool could take hours of debugging opaque conda errors. Of course, those proteins that we tested here are not real therapeutics. They completed only the first step of the process: demonstrating that they can function as binders. Still, this study shows a path towards making actual therapeutics with AI. Imagine making a drug is like climbing a mountain. We have clearly been able to climb some mountains, as humanity has made many drugs already. But the way to the top is a dangerous narrow path and climbing it takes many years and costs billions of dollars (and the lives of many biotechs). The goal of AI for drug discovery is turning this narrow mountain path into a highway, making it easier and cheaper to get to the top so that we can develop 100x more therapeutics than we have right now. Similarly, writing code was a more of a high-expertise craft before LLMs, now it’s mostly automated and it has made generating software accessible for anyone.
Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work. We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets. We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
24
53
9
356
31,887
Peter Halliburton retweeted
Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work. We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets. We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
599
1,431
671
12,421
4,355,615
My zinnias are digging this weather! 🌼
1
83